• SLS was the clearest explicit short, but no rationale, price target, or timeframe was provided; treat it as a high-risk idea and verify the thesis before acting.
• INTC was viewed bearishly, with $40 or lower cited as a possible downside; no timeframe was given.
• CRWV faces debt and funding concerns that could pressure AI-infrastructure stocks, but bankruptcy risk was raised as a concern—not a confirmed outcome—so avoid treating the reported 50% prediction-market odds as a forecast.
• Treat Anthropic’s Investor Day as a potential volatility catalyst, not a directional trade; watch for Q3 performance and 2026–2027 guidance.

Anthropic (Private)

• The episode focused on Anthropic’s Investor Day, which one institutional investor reportedly called “D-Day.” The speaker said expectations were very high and that the company could disappoint the market.
• He expected news or leaks to move the market sharply, but said the direction was uncertain. He suggested investors would look for information about the company’s Q3 performance and 2026–2027 guidance.

Takeaways

• Treat the event as a potential volatility catalyst, not as a clear bullish or bearish signal. The transcript offers no specific financial forecasts or valuation for Anthropic.

OpenAI (Private)

• The speaker cited a recent OpenAI event as an example of how high expectations can set up a disappointing market reaction.
• OpenAI was also mentioned in connection with a report that eight states had sued the company, alleging ChatGPT is harmful to children.

Takeaways

• The discussion highlights both expectation risk and regulatory or legal headlines for major AI companies. No investment recommendation or valuation was given.

CoreWeave (CRWV)

• The speaker described CoreWeave as one of NVIDIA’s biggest customers and warned that financial trouble there could weigh on semiconductor and AI-infrastructure stocks.
• He raised bankruptcy risk as a concern, citing the company’s debt and a reported disconnect between its bonds and stock. He also said CoreWeave management had previously talked him out of that view.
• He characterized the situation as a possible “crisis of confidence” and said a likely scenario could be a prolonged period of fear before the company’s situation stabilizes. He floated a hypothetical bailout in which NVIDIA could provide $10 billion in equity.
• A prediction market was said to be pricing a 50% chance of bankruptcy; this was not presented as the speaker’s own estimate.
• The speaker recalled shorting CoreWeave near $100, getting squeezed as the stock rose from roughly $80 to $120, and said he should have stuck to his view.

Takeaways

• The central risk discussed is CoreWeave’s ability to fund its large debt and continue buying infrastructure. The speaker’s view was cautious, but he also acknowledged that management had previously reassured him and that the company might weather the current fears.

Nebius (NBIS)

• Nebius was described as being caught up in the selloff in AI infrastructure stocks. The speaker grouped it with CoreWeave as part of the market’s concerns about the AI “food chain.”
• He asked whether CoreWeave and Nebius had found a bottom, but did not offer a firm conclusion.

Takeaways

• The discussion points to sensitivity to financing and demand concerns across AI cloud providers. No specific price target or direct recommendation was given.

NVIDIA (NVDA)

• The speaker said NVIDIA could be vulnerable if CoreWeave’s financial problems spread, because CoreWeave is a major customer.
• He questioned how NVIDIA could keep growing if customers were already spending at very high levels. In a hypothetical downside scenario tied to broader AI-infrastructure weakness, he cited $100 as a possible NVIDIA share price.

Takeaways

• The key issue raised is whether customers’ AI spending can keep growing enough to support continued sales growth. The $100 figure was a conditional downside scenario, not a stated price target.

Micron (MU)

• The speaker said Micron might be less affected than expected by the CoreWeave concerns, while warning that the company could face pressure if the AI infrastructure downturn spread.
• He cited $200 as a possible downside price in that conditional scenario.
• He also noted Elon Musk’s criticism of memory suppliers, calling Micron “responsible” while describing SK Hynix and Samsung as “extortionate.”

Takeaways

• The transcript raises questions about both AI-related demand and customer pricing power. The $200 figure was a hypothetical downside case, not a formal target.

SanDisk (SNDK)

• The speaker said SanDisk could be hurt if CoreWeave’s troubles spread through the AI infrastructure sector.
• He cited $300 as a possible downside price in that conditional scenario.

Takeaways

• The risk discussed is that high spending by AI customers may not be sustainable. The $300 figure was an illustrative downside scenario, not a stated price target.

Oracle (ORCL)

• The speaker said CoreWeave’s situation was “really bearish” for Oracle as well, comparing the companies’ positions in the AI infrastructure market.

Takeaways

• The concern is exposure to major AI infrastructure commitments if customer demand or financing weakens. No specific price target was given.

Meta Platforms (META)

• The speaker said Meta may eventually moderate its spending and argued it would not spend $100 billion or $200 billion per year forever.
• He suggested that future spending moderation could make some AI-related stocks attractive shorts, though he did not give a direct price target or timing for Meta.

Takeaways

• Watch whether Meta’s heavy AI spending translates into revenue growth and whether spending continues at its current pace. The speaker’s concern was about long-term spending sustainability, not an immediate forecast.

Intel (INTC)

• The speaker said Intel was up sharply, adding that it could fall to $40 or lower. He also noted that demand was supposed to be strong, highlighting the tension between expected demand and market pricing.

Takeaways

• The speaker expressed a bearish view on the stock despite expectations of strong demand. The $40 figure was his stated downside view; no timeline was given.

ASML (ASML)

• The speaker questioned whether investors should be long ASML, emphasizing that future spending matters more than past spending.
• He said ASML’s results looked “pretty good” and suggested reviewing them and updating the company model.

Takeaways

• The discussion supports focusing on future customer spending and earnings rather than extrapolating from past demand. The transcript contains no explicit buy or sell recommendation.

Tower Semiconductor (TSEM)

• Tower Semiconductor was mentioned as a stock to review, but the speaker gave no specific view on its business or valuation.

Takeaways

• No actionable investment thesis was provided in the discussion.

Taiwan Semiconductor Manufacturing Company (TSM)

• The speaker was asked whether TSM would rise the next day and why Keith did not like it, but no clear answer or investment view was provided.

Takeaways

• The transcript does not offer enough information to infer a recommendation or outlook.

SK Hynix (000660.KS) and Samsung Electronics (005930.KS)

• Elon Musk was reported as calling Micron a responsible DRAM supplier while describing Hynix and Samsung as “extortionate.” The speaker called the comment interesting but did not provide his own detailed view of either company.

Takeaways

• The mention raises a potential customer-pricing concern for memory suppliers, but the transcript does not establish whether the speaker agreed with Musk’s characterization.

Seagate Technology (STX)

• Seagate was mentioned among companies for which the speaker questioned how growth could continue if customers were already spending at very high levels.

Takeaways

• The key issue raised is whether customer spending can keep expanding enough to support further growth. No specific recommendation or target was given.

IonQ (IONQ)

• IonQ was down 7% during the session, according to the speaker.

Takeaways

• The transcript reports a sharp daily decline but gives no company-specific explanation or investment thesis.

Rigetti Computing (RGTI)

• Rigetti was down 5% during the session, according to the speaker.

Takeaways

• The stock was discussed as part of a broader weak day for quantum-computing names. No specific outlook was provided.

SELLAS Life Sciences (SLS)

• The speaker said he thought SLS was a “great short.”

Takeaways

• This was an explicit bearish opinion, but the transcript did not include the reasoning, a price target, or a timeline.

Disc Medicine (IRON)

• The speaker said Disc Medicine had a market capitalization of about $2.2 billion and that he did not have a model for the company but planned to build one.
• He mentioned upcoming top-line data from the Apollo study of bitopertin and referred to the company’s work in myelofibrosis.

Takeaways

• The upcoming study data is a potential catalyst mentioned in the discussion. The speaker had not yet completed his analysis, so the transcript does not establish a bullish or bearish view.

Arrowhead Pharmaceuticals (ARWR)

• The speaker said Arrowhead was up about 2% and highlighted reductions of up to 73% in healthy volunteers.
• He described the prospect of getting the treatment into the brain as impressive and bullish.

Takeaways

• The speaker expressed a positive view of the reported results and potential delivery approach. The transcript does not identify a price target or clinical timeline.

Liquidia (LQDA)

• The speaker repeatedly described a settlement as positive and said it avoided the risk that the drug would be pulled from the market.
• He called the outcome a “great settlement,” while noting that the settlement had restrictive features, including limits on off-label marketing. He expected prescriptions to continue, but to be somewhat limited.
• He said the stock was lower than he had expected despite the settlement.

Takeaways

• The settlement appears to reduce the risk of the drug being removed from the market, while leaving restrictions that may limit commercial potential. The speaker was broadly positive about the outcome but noted that the stock reaction was weaker than he expected.

Moderna (MRNA)

• Moderna was described as a short by the speaker, who also said he did not understand why the stock was rising.
• The stock was mentioned as being heavily sold off earlier in the discussion, adding to the mixed short-term price action noted during the episode.

Takeaways

• The speaker’s stated view was bearish, but he gave no supporting valuation analysis, price target, or timeline.

Spruce Biosciences (SPRB)

• The speaker said he liked Spruce and described it as a good discount. He also said he was “very bullish” on the company.

Takeaways

• This was an explicit positive view. The transcript did not provide a valuation, price target, or specific catalyst.

Rocket Lab (RKLB)

• A company update read during the episode said Rocket Lab had moved Neutron’s first launch into next year after finding voids in the carbon-composite material used for a propellant dome.
• The company said it had identified and addressed the manufacturing issue in testing. A new dome was being built, with inspection and stage testing planned; it expected the first two steps to be completed before Q1, with the next assembly and testing stage completed during that quarter.
• Rocket Lab said it would provide a more specific launch date after those milestones. It emphasized that it was prioritizing reliability over rushing to launch and said it expected to discuss new Neutron contracts later.

Takeaways

• The delay is a clear execution and timing risk for Neutron, while the company presented the manufacturing fix and customer demand as reasons for confidence in the program’s longer-term prospects. The update did not provide a new launch date.

Oklo (OKLO)

• The speaker said it was hard for him to buy Oklo, while adding that he believed nuclear power was the future.

Takeaways

• The comment reflects a positive view of the nuclear-energy theme but hesitation about this particular investment. No valuation or reason for the hesitation was provided.

Praxis Precision Medicines (PRAX)

• The speaker said he thought “everyone likes Praxis,” but gave no additional analysis.

Takeaways

• The mention suggests a favorable impression, but it is not a clear personal recommendation or investment thesis.

AI Drug Discovery (Investment Theme)

• The speaker was strongly skeptical that AI would discover new drugs or materially speed drug development. He argued that designing a molecule is not the main bottleneck and said clinical trials still need to be conducted.
• He acknowledged that AI could help with tasks such as reviewing large amounts of information and paperwork, but dismissed a claim that AI could shorten clinical trials by 10–20 months as unsupported.

Takeaways

• The speaker’s view was bearish toward claims that AI will quickly transform drug discovery. Investors considering this theme should distinguish between AI tools that support research and claims that AI will eliminate clinical or regulatory requirements.

Bitcoin (BTC) and Perpetual Futures

• Bitcoin was mentioned only as an example in a discussion about trading perpetual futures. The speaker challenged the idea of trading perps on Bitcoin but said he had traded perps before and was associated with a perp-trading software sponsor.

Takeaways

• No view on Bitcoin’s value or price direction was given. The exchange was about trading products, not an investment thesis on the cryptocurrency.